| Trial ID: | L0073 |
| Source ID: | NCT05219942
|
| Associated Drug: |
Glargine
|
| Title: |
Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases
|
| Interventions: |
DRUG: Glargine|OTHER: normal saline
|
| Outcome Measures: |
Primary: Mean time to reversal of diabetic ketoacidosis, Resolution of DKA is defined as blood sugar \<200mg/dl plus any two of serum bicarbonate ≥15,pH\>7.3, and anion gap less than or equal to 12, 48 hours|Total crystalline insulin consumption, Total number of units of insulin infusion consumed for diabetic ketocidosis to resolve, 48 hours |
|
| Sponsor/Collaborators: |
Sponsor: Ain Shams University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
52
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2020-12-01
|
| Completion Date: |
2022-07
|
| Results First Posted: |
|
| Last Update Posted: |
2022-06-07
|
| Locations: |
Ain Shams University, Cairo, 11566, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05219942
|
